The CANOVA Study Real-World Evidence of Biologic Treatments in Moderate-Severe Psoriasis in Italy: A Gender Perspective.

Autor:	Colombo D; Novartis Farma S.p.A, Italy.; Pharmacologist and Dermatologist Private Office, Milan, Italy., Bianchi L; Policlinico Tor Vergata, Rome, Italy., Fabbrocini G; A.O.U. Federico II, Naples, Italy., Corrao S; ARNAS Civico, Palermo, Italy., Offidani A; A.O.U. Riuniti Umberto I Lancisi Salesi, Ancona, Italy., Stingeni L; Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy., Costanzo A; IRCCS Istituto Clinico Humanitas, Rozzano, Italy., Pellacani G; A.O.U. Policlinico, Modena, Italy., Peris K; Fondazione Policlinico Universitario A. Gemelli-IRCCS e Università Cattolica, Rome, Italy., Bardazzi F; A.O.U. Policlinico S.Orsola-Malpighi, Bologna, Italy., Argenziano G; Dermatology Unit, University of Campania, Naples, Italy., Ruffolo S; A.O. Cosenza Ospedale SS Annunziata, Cosenza, Italy., Dapavo P; A.O.U. Città della Salute e della Scienza PO Molinette, Turin, Italy., Carrera C; Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy., Fargnoli MC; Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Parodi A; Clinica Dermatologica DiSSal Università di Genova/Ospedale-Policlinico San Martino IRCCS, Genova, Italy., Romanelli M; A.O.U. Pisana Ospedale Santa Chiara, Pisa, Italy., Malagoli P; Policlinico San Donato, San Donato M.se, Italy., Zullo A; MediNeos Observational Research, Modena, Italy., Ferri F; MediNeos Observational Research, Modena, Italy., Fiocchi M; Novartis Farma S.p.A, Italy., Zagni E; Novartis Farma S.p.A, Italy.
Jazyk:	angličtina
Zdroj:	Women's health reports (New Rochelle, N.Y.) [Womens Health Rep (New Rochelle)] 2022 May 02; Vol. 3 (1), pp. 450-457. Date of Electronic Publication: 2022 May 02 (Print Publication: 2022).
DOI:	10.1089/whr.2021.0124
Abstrakt:	Background: In psoriasis, several studies have indicated sex differences in clinical characteristics, type of treatment, and outcomes. A higher impact of psoriasis on quality of life (QoL) and a lower treatment satisfaction have been reported in women by different authors. Objectives: This article reports the results of a post hoc gender analysis of CANOVA study, aimed at assessing 16/24/52-week effectiveness of biologics in patients with moderate-severe plaque psoriasis. Materials and Methods: CANOVA was a real-world, multicenter, noninterventional, retro-prospective study conducted in 17 Italian hospital dermatology clinics. Results: Of the 669 eligible patients, 63.8% were men. Demographic and baseline characteristics and duration of disease were rather homogeneous between sexes. Slightly more women had been treated with biologics (50.4% vs. 46.5%) and had received ≥2 biologic treatment lines (17.2% vs. 12.4%) before study treatment. The most frequently used biologics were secukinumab, ustekinumab, adalimumab, and ixekizumab in both sexes. At 6 months, Psoriasis Area Severity Index (PASI) 75/90/100 responders were 90.8%/72.3%/45.3% of men and 89.2%/76.6%/48.2% of women. Sustained PASI responders were 79.5% of men and 75.9% of women. Treatment satisfaction was significantly lower in women at enrolment for all subscales, and was still lower at 6 months, no longer significantly. Gender distribution in Dermatology Life Quality Index total score classes showed a significantly greater effect of psoriasis on QoL in women, both at enrolment and at the 6-month follow-up. Conclusions: In conclusion, this gender analysis confirms in both genders the efficacy of biologics in psoriasis. However, women reported a greater impact of the disease on QoL and lower treatment satisfaction. Competing Interests: D.C. was a part-time employee of Novartis Farma Italy when the research was conducted. F.F. is an employee of MediNeos Observational Research (Modena, Italy), hired by Novartis Farma Italy, responsible for the design and conduction of the CANOVA study, as well as scientific support, clinical operations, data management, and statistical analysis. A.Z. is an employee of MediNeos Observational Research (Modena, Italy), hired by Novartis Farma Italy, responsible for the design and conduction of the CANOVA study, as well as scientific support, clinical operations, data management, and statistical analysis. M.F. is an employee of Novartis Farma Italy. E.Z. is an employee of Novartis Farma Italy. G.F. acted as a speaker or consultant for Abbvie, Almirall, Amgen, Eli Lilly, Janssen, Leo Pharma, Novartis and UCB. No further conflict of interests was declared. (© Delia Colombo et al., 2022; Published by Mary Ann Liebert, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu